Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of myeloproliferative diseases globally
3.2.1.2 Increasing R&D efforts to develop new drugs
3.2.1.3 Growing advancement in targeted therapies
3.2.1.4 Increasing geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited treatment options
3.2.2.2 High cost of treatment
3.2.2.3 Adverse effects associated with the drugs
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players,
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Disorder Type, 2018-2032 ($ Million)
5.1 Key trends
5.2 Philadelphia chromosome-positive (Ph+) CML
5.3 Philadelphia chromosome-negative (Ph-) MPNs
5.3.1 Polycythemia vera
5.3.2 Essential thrombocythemia
5.3.3 Myelofibrosis
5.4 Other disorder types
Chapter 6 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)
6.1 Key trends
6.2 Tyrosine kinase inhibitors
6.3 Janus kinase inhibitors
6.4 Hydroxyurea
6.5 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Million)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Bristol-Myers Squibb Company
10.3 Eli Lilly and Company
10.4 GlaxoSmithKline plc (GSK)
10.5 GL Pharma GmbH
10.6 Incyte Corporation
10.7 Janssen Biotech, Inc. (Johnson & Johnson)
10.8 MorphoSys AG
10.9 Mylan N.V. (Viatris)
10.10 Novartis Pharmaceuticals Corporation (Novartis AG)
10.11 Takeda Pharmaceutical Company Limited
10.12 Teva Pharmaceutical Industries Ltd.
